A Phase I, Parallel, Open-Label Study of the Safety and Tolerability, Pharmacokinetics, and Antileukemic Activity of ASTX660 as a Single Agent and in Combination with ASTX727 in Subjects with Acute Myeloid Leukemia
A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan GMI-1271 in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
A Measurable Residual Disease MRD Focused, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH SubStudy
A Phase II, Open-label, Randomized, Two-stage Clinical Study
of Alvocidib in Patients with Relapsed/Refractory Acute
Myeloid Leukemia Following Treatment with Venetoclax
Combination Therapy
Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
Phase I study of venetoclax/azacitidine or venetoclax in combination with ziftomenib KO-539 or standard induction cytarabine/daunorubicin 7+3 chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia
A Multicenter, Pivotal Phase 3 Study of Iomab-B Prior to Allogeneic Hematopoietic Cell Transplantation versus Conventional Care in Older Subjects with Active, Relapsed or Refractory Acute Myeloid Leukemia.
A Phase IB/IIA, Open-Label Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of Fosciclopirox Alone And In Combination With Cytarabine In Patients With Relapsed/Refractory Acute Myeloid Leukemia
V-FAST: A Phase IB Master Trial to Investigate CPX-351 Combined with Various Targeted Agents in Subjects with Previously Untreated Acute Myeloid Leukemia